Key result
Adjuvant chemotherapy following amputation increased 5-year disease-free survival to 34.0% compared to 7.0% with surgery alone in patients with local osteogenic sarcoma.
Why the study?
Does adjuvant chemotherapy improve disease-free survival in patients with osteogenic sarcoma compared to surgery alone?
Population
313 patients (246 with local osteogenic sarcoma and 67 with pulmonary metastases)
Comparison
Surgery combined with various modalities of… vs Surgery alone
Design
Cohort, not randomized
Follow-up
up to 5 years
Authors
Loading...
Adjuvant chemotherapy may improve DFS after amputation; leaves open need for randomized confirmation in osteogenic sarcoma.
Cohort (n=313)
No
Does adjuvant chemotherapy improve disease-free survival in patients with osteogenic sarcoma compared to surgery alone?
Absolute Event Rate: 34% vs 7%
Adjuvant chemotherapy significantly improves disease-free survival in patients with osteogenic sarcoma compared to surgery alone.
Трапезников et al. (1986) conducted a cohort in Osteogenic sarcoma (n=313). Adjuvant chemotherapy vs. Surgery alone was evaluated on 5-year disease-free survival. Adjuvant chemotherapy following amputation increased 5-year disease-free survival to 34.0% compared to 7.0% with surgery alone in patients with local osteogenic sarcoma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: